Research Article

You have full text access to this OnlineOpen article

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data

  1. X. Baraliakos1,†,
  2. J. Brandt1,†,
  3. J. Listing2,
  4. H. Haibel3,
  5. H. Sörensen4,
  6. M. Rudwaleit3,
  7. J. Sieper3,
  8. J. Braun1,*

Article first published online: 7 DEC 2005

DOI: 10.1002/art.21588

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 53, Issue 6, pages 856–863, 15 December 2005

Additional Information

How to Cite

Baraliakos, X., Brandt, J., Listing, J., Haibel, H., Sörensen, H., Rudwaleit, M., Sieper, J. and Braun, J. (2005), Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Arthritis & Rheumatism, 53: 856–863. doi: 10.1002/art.21588

Author Information

  1. 1

    Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Bochum, Germany

  2. 2

    German Rheumatism Research Center, Berlin, Germany

  3. 3

    Charité Medical University Berlin, Campus Benjamin Franklin, Berlin, Germany

  4. 4

    Private Praxis, Berlin, Germany

  1. †

    Drs. Baraliakos and Brandt contributed equally to this work.

*Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany

Publication History

  1. Issue published online: 7 DEC 2005
  2. Article first published online: 7 DEC 2005
  3. Manuscript Accepted: 16 JUN 2005
  4. Manuscript Received: 17 MAR 2005

Funded by

  • German Ministry of Research
  • Wyeth Pharma, Muenster, Germany

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (126K)

REFERENCES

  • 1
    Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58–67.
    Direct Link:
  • 2
    Zink A, Listing J, Klindworth C, Zeidler H, and the German Collaborative Arthritis Centres. The national database of the German Collaborative Arthritis Centres. I. Structure, aims, and patients. Ann Rheum Dis 2001; 60: 199–206.
  • 3
    Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001; 60: 353–8.
  • 4
    Chorus AM, Boonen A, Miedema HS, van der Linden S. Employment perspectives of patients with ankylosing spondylitis. Ann Rheum Dis 2002; 61: 693–9.
  • 5
    Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002; 41: 1330–2.
  • 6
    Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995; 22: 1104–7.
  • 7
    Braun J, Alten R, Burmester G, Ebner W, Gomor B, Grasedyck K, et al. Efficacy of sulfasalazine in undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicenter randomized controlled trial. Berlin: Annual European Congress of Rheumatology; 2004.
  • 8
    Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42: 2325–9.
    Direct Link:
  • 9
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667–75.
    Direct Link:
  • 10
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349–56.
  • 11
    Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–6.
    Direct Link:
  • 12
    Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis [letter]. Arthritis Rheum 2004; 51: 302–4.
    Direct Link:
  • 13
    Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis [published erratum appears in Rheumatology (Oxford) 2005;44:569]. Rheumatology (Oxford) 2005; 44: 342–8.
  • 14
    Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis treatment with etanercept. Ann Rheum Dis 2005; 64: 1305–10.
  • 15
    Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216–23.
    Direct Link:
  • 16
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91.
  • 17
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
  • 18
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–5.
  • 19
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694–8.
  • 20
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
  • 21
    Medical outcome trust: how to score the SF-36 health survey. Boston (MA); 1994.
  • 22
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876–86.
    Direct Link:
  • 23
    Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1438–44.
  • 24
    Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7: R439–44.
  • 25
    Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24: 697–735.
  • 26
    Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 1126–36.
    Direct Link:
  • 27
    Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1670–2.
  • 28
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594–600.
  • 29
    Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis: a twenty-six–week, placebo-controlled clinical trial. Arthritis Rheum 1988; 31: 1111–6.
  • 30
    Ostendorf B, Specker C, Schneider M. Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared to psoriatic arthritis and rheumatoid arthritis. J Clin Rheumatol 1998; 4: 129–36.
  • 31
    Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005; 64: 730–4.
  • 32
    Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216–23.
    Direct Link:
  • 33
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31: 531–8.
  • 34
    Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112–7.
    Direct Link:
  • 35
    Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22–8.
  • 36
    Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088–94.
  • 37
    Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774–85.
  • 38
    Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48: 780–90.
    Direct Link:
  • 39
    Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003; 62: 561–4.
  • 40
    Mielants H, Veys EM, Cuvelier C, de Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996; 10: 147–64.
  • 41
    Van den Bosch F, Kruithof E, de Vos M, de Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821–2.
  • 42
    Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002; 20 Suppl 28: S152–7.
  • 43
    Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740–51.
    Direct Link:
  • 44
    Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004; 45 Suppl 2: S3–9.
View Full Article (HTML) Get PDF (126K)